Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMA: Inhaled Molgramostim for NTM
NCT03421743Phase 2Completed
- Sponsor
- Savara
- Start
- Mar 2018
- Primary completion
- Oct 2019
- Modality
- Cytokines & Interferons
- Countries
- 2
01
Overview
A Phase 2 trial of molgramostim in Nontuberculous Mycobacterial Lung Disease (NTM-LD), sponsored by Savara. Started Mar 2018; status: completed.
02
Drugs
molgramostim
03
Conditions
Nontuberculous Mycobacterial Lung Disease (NTM-LD)
Beyond the preview
Go deeper on NCT03421743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03421743.